Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 67
Selected: 0
NCT IDTitle
NCT03164772Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC
NCT01975831A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
NCT02659540Pilot Study of the Safety/Efficacy of Combination Checkpoint Blockade + External Beam Radiotherapy in Stage IV Melanoma
NCT03017326Paediatric Hepatic International Tumour Trial
NCT06518837Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer
NCT00199888Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.
NCT00106158Safety Study of NY-ESO-1 Protein Vaccine to Treat Cancer Expressing NY-ESO-1
NCT00142415Phase I/II Dose-escalation Study of Lutetium-177-labeled cG250 in Patients With Advanced Renal Cancer
NCT00803569Vaccine Therapy in Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
NCT00006099Monoclonal Antibody Therapy in Treating Patients Scheduled for Surgery to Remove Ovarian Cancer
NCT01380145MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
NCT00084799Monoclonal Antibody Therapy in Treating Patients With Progressive Small Cell Lung Cancer (SCLC)
NCT00199901Study of NY-ESO-1 ISCOMATRIX® in Patients With High-risk, Resected Melanoma
NCT02963831A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies
NCT01498172BCG Modulation of the recMAGE-A3 + AS15 ASCI Response in the Treatment of Non Muscle Invasive Bladder Cancer (NMIBC) Patients
NCT00003102Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
NCT01810016NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
NCT00616941Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT00140855A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial Sarcoma
NCT00199797Phase I Trial of huA33 Plus Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT00679289Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma
NCT00112957Vaccine Therapy in Patients With Stage II, III, or IV Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
NCT02431559Phase 1/2 Study of Motolimod, Doxorubicin, and Durvalumab in Recurrent, Platinum-Resistant Ovarian Cancer
NCT00112242Immunotherapy of Stage III/IV Melanoma Patients
NCT01079741Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
NCT01689870Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma
NCT00199862Safety Study of Radio-labeled huA33 Antibody in Colorectal Cancer
NCT00293215Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
NCT02716805Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant
NCT00291473Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers
NCT00518206Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma
NCT01490047Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas
NCT00299728NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors
NCT02735239Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
NCT00070070Vaccine Therapy in Treating Patients With Transitional Cell Carcinomas
NCT00142454NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
NCT01266018Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer
NCT02336165Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma
NCT06002802Study on Infectious Mononucleosis in Munich
NCT00199875Treatment of Patients With Advanced Renal Cancer With a Radiolabeled Antibody, Yttrium-90 Conjugated Chimeric G250
NCT00199849NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine
NCT00199836A Pilot Study of NY-ESO-1b Peptide Plus CpG 7909 and Montanide® ISA-51 in Patients With Cancer.
NCT02252211Safety and Bioimaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
NCT01838200Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma
NCT00145145Immunization With the MAGE-3.A1 Peptide Mixed With the Adjuvant CpG 7909 in Patients With Metastatic Melanoma
NCT01131169Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions
NCT04729543MAGE-C2 TCR T Cell Trial to Treat Melanoma and Head and Neck Cancer
NCT02046733Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
NCT00145158Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
NCT00066729Vaccine Therapy in Treating Patients With Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer